Healios K.K. (FRA:6VX)

Market Cap	259.60M +52.3%
Revenue (ttm)	564.95K -81.4%
Net Income	-12.04M
EPS	-0.14
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	1.770
Previous Close	1.830
Day's Range	1.770 - 1.770
52-Week Range	1.380 - 4.040
Beta	n/a
RSI	44.17
Earnings Date	May 14, 2026

About Healios K.K.

Healios K.K., together with its subsidiaries, engages in the research, development, manufacturing, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051, which is preparing for approval for the treatment of acute respiratory distress syndrome; HLCM051, which is preparing for phase 3 clinical trial for the treatment of ischemic stroke; and HLCM051, which is in phase 2 clinical trial for the treatment of trauma, as well as HLCR011, which is in phase 1/2 clinical trial for t...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2011
• Employees: 75
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6VX

Financial Performance

In 2025, Healios K.K.'s revenue was 104.00 million, a decrease of -81.43% compared to the previous year's 560.00 million. Losses were -2.22 billion, -47.65% less than in 2024.

Financial numbers in JPY